Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2017

BOSTON, March 6, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Alicia Secor, President and Chief Executive Officer, will present at the 29^th Annual ROTH Conference as follows:

Juniper's presentation will be webcast live via www.juniperpharma.com under the 'Investors' tab, or click here.  The webcast will be archived for 90 days at the aforementioned URLs.

In addition to the live presentation, Ms. Secor, Jeff Young, Juniper's Chief Financial Officer, and Dr. Bridget Martell, Juniper's Chief Medical Officer, will be available for one-on-one meetings with investors who are registered to attend the conference.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the Crinone® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Contact
Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 / ir@juniperpharma.com

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.

Follow us on LinkedIn  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-present-at-roth-conference-on-march-14-2017-300418509.html

SOURCE Juniper Pharmaceuticals, Inc.